

10 July 2020

Our Ref: RFI 34748

Dear

**Freedom of Information Act 2000
Information Relating to Medications Prescribed to Cancer Patients**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above which you requested on 5 June 2020. You will be aware from my previous email that due to the Covid- 19 Pandemic the Information Governance Service was suspended as staff were redeployed. Thank you for your patience and forbearance during the ensuing delay.

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Rebecca Manning
Information Governance Assistant

Q1. Within your health trust how many patients are currently [within the past 3 months] being treated for metastatic Non-small-cell lung cancer (NSCLC) with the following:

A1 The number of patients treated (within the last 3 months) with the specified treatments, within the Trust, are detailed in Table 1 below:

Table 1

Treatment	Number of Patients treated
Afatinib	2
Atezolizumab monotherapy or combination	5
Brigatinib	0
Ceretinib	0
Crizotinib	2
Docetaxel mono or combination	0
Erlotinib	0
Gefitinib	8
Gemcitabine	16
Nitendanib + docetaxel	0
Nivolumab	0
Osimertinib	4
Paclitaxel	0
Pembrolizumab monotherapy	8
Pembrolizumab chemo in combination	0
Pembrolizumab monotherapy	repeat
Pemetrexed monotherapy of combination with Carboplatin/Cisplatin	10
Ramucirumab	0
Vinorelbine mono or combination	0
Other active systemic anti-cancer therapy	0
Palliative care only	

Q2. Out of the metastatic NSCLC patients currently [within the past 3 months] being treated, are you able to provide the number of patients being treated for Squamous Cell Non-small-cell lung cancer (SqNSCLC) with the following products?

Afatinib; Atezolizumab monotherapy or combination; Brigatinib; Ceretinib; Crizotinib; Docetaxel mono or combination; Erlotinib; Gefitinib; Gemcitabine; Nitendanib + docetaxel; Nivolumab; Osimertinib; Paclitaxel; Pembrolizumab monotherapy; Pembrolizumab chemo in combination; Pembrolizumab monotherapy; Pemetrexed monotherapy of combination with Carboplatin/Cisplatin; Ramucirumab; Vinorelbine mono or combination; Other active systemic anti-cancer therapy; Palliative care only.

A2 Unfortunately the Trust are unable to provide this level of detail without a detailed audit involving numerous electronic systems and review of notes systems that include cross Trust systems.

This would exceed the 'Appropriate Limit' as defined by the Freedom of Information Act 2000. The Trust therefore exempts the release of this information under Section 12(1).

12.-(1) Section 1 (1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.